 |
3 Products |  |
1 Disease | | 3 Products |
|
6 Trials |  |
81 News |  |
| «123 |
- GB0139 / BMS, Galecto
[VIRTUAL] Galactic-1: A Randomized, Double-Blind, Multicentre, Parallel, Placebo-Controlled Phase 2b Study in Subjects with Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered via a Dry Powder Inhaler Over 52 Weeks (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3921;
This study represents the first Phase 2b study with an inhaled therapy. With the favourable toxicity profile and biomarker changes observed in the initial FIH studies and the unique pharmacological profile with proven target engagement in the lung, TD139 promises to be an exciting novel therapy for IPF.
- GB0139 / BMS, Galecto
[VIRTUAL] Translational Pharmacology of TD139, an Inhaled Small Molecule Galectin-3 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_312;
Pre-clinical in vitro and in vivo studies have shown to be clinically translatable. This study supported the progression of TD139 into a phase IIb IPF study[3].
- | olitigaltin (GB0139) / Galecto
New P2 trial: Investigating potential new therapies for COVID-19. (EUDRACT) - Jul 4, 2020
P2, N=100, Ongoing, Sponsor: University of Edinburgh`NHS Lothian
- | New P2 trial: A Phase 2 Study for the Treatment of COVID 19 in Hospitalised Patients (EUDRACT) - Apr 30, 2020
P2, N=825, Ongoing, Sponsor: University Hospital Southampton NHS Foundation Trust
- || olitigaltin (GB0139) / Galecto
Trial completion date, Trial primary completion date: GALACTIC-1: A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Apr 28, 2020
P2b, N=450, Recruiting, Sponsor: Galecto Biotech AB
This study supported the progression of TD139 into a phase IIb IPF study[3]. Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021
- TD139 / BMS, Galecto
Galactic-1: A Randomized, Double-Blind, Multicentre, Parallel, Placebo-Controlled Phase 2b Study in Subjects with Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered via a Dry Powder Inhaler Over 52 Weeks (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area J) - Mar 15, 2020 - Abstract #ATS2020ATS_6339;
This study represents the first Phase 2b study with an inhaled therapy. With the favourable toxicity profile and biomarker changes observed in the initial FIH studies and the unique pharmacological profile with proven target engagement in the lung, TD139 promises to be an exciting novel therapy for IPF.
- TD139 / BMS, Galecto
Translational Pharmacology of TD139, an Inhaled Small Molecule Galectin-3 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis (PENNSYLVANIA CONVENTION CENTER, Room 118 A (100 Level)) - Mar 15, 2020 - Abstract #ATS2020ATS_2986;
Pre-clinical in vitro and in vivo studies have shown to be clinically translatable. This study supported the progression of TD139 into a phase IIb IPF study[3].
- TD139 / BMS, Galecto
Discovery of GB1211, the first orally available galectin/galectin-3 inhibitor to be taken into clinic studies as a potential treatment for organ fibrosis (Grand Ballroom B, Pennsylvania Convention Center) - Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_15928;
This compound recently entered Phase IIb trials after a successful phase I/IIa trial, where TD139 demonstrated a significant effect on biomarkers associated with IPF progression. We herein present a new series of high affinity and orally available galectin-3 inhibitors.[5] This lecture will discuss the pharmacology of galectin- 3 and the discovery process leading up to selection of GB1211, the first orally available galectin inhibitor taken to clinical studies, GB1211, and the progress of this molecule in the clinic to date.
- TD139 / BMS, Galecto
Galectin-3 Promotes CXCR2 Expression in Medulloblastoma (Ballroom Lawn) - Oct 29, 2019 - Abstract #SNO2019SNO_1219;
Among the Gal family, Gal-3 in particular was highly expressed in MB tumor slices. To further investigate Gal-3's role in the pathophysiology of MB, we used either small interfering RNA (siRNA) to knock down Gal-3 expression or Gal-3 inhibitor, TD139 to suppress Gal-3 expression in ex vivo slice culture model...These results indicate that highly expressed Gal-3 may up-regulate CXCR2 to augment MB invasiveness and progression. Gal-3 may be a prognostic and innovative target for the treatment of MB.
- TD139 / BMS, Galecto
Galectin-3 as a Potential Therapeutic Target in Recurrent Atypical and Malignant Meningioma (Ballroom Lawn) - Oct 29, 2019 - Abstract #SNO2019SNO_1065;
Furthermore, we demonstrated that TD139 inhibits MM growth in an in vivo xenograft MM model. Taken together, our results suggest that Gal-3 modulates uPAR expression and that Gal-3 may be a potential therapeutic target for the treatment of atypical and malignant meningiomas.
- | lenumlostat (GB2064) / Galecto
New P2 trial: PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis (clinicaltrials.gov) - Aug 12, 2019
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- | TD139 / BMS, Galecto
Clinical, Journal: The effects of tandem skiing on posture and heart rate in children with profound intellectual and multiple disabilities. (Pubmed Central) - May 30, 2019
Taken together, our results suggest that Gal-3 modulates uPAR expression and that Gal-3 may be a potential therapeutic target for the treatment of atypical and malignant meningiomas. In children with PIMD, TS elicits active postural control associated with cardiac activities similar to that of the controls.
- |||| olitigaltin (GB0139) / Galecto
Enrollment open: GALACTIC-1: A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Feb 21, 2019
P2b, N=450, Recruiting, Sponsor: Galecto Biotech AB
In children with PIMD, TS elicits active postural control associated with cardiac activities similar to that of the controls. Not yet recruiting --> Recruiting
- |||||| olitigaltin (GB0139) / Galecto
New P2b trial: GALACTIC-1: A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) (clinicaltrials.gov) - Feb 6, 2019
P2b, N=450, Not yet recruiting, Sponsor: Galecto Biotech AB
- ||| selvigaltin (GB1211) / Galecto
Enrollment open: A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects (clinicaltrials.gov) - Jan 24, 2019
P1, N=87, Recruiting, Sponsor: Galecto Biotech AB
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| selvigaltin (GB1211) / Galecto
New P1 trial: A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects (clinicaltrials.gov) - Jan 18, 2019
P1, N=87, Not yet recruiting, Sponsor: Galecto Biotech AB
- |||| olitigaltin (GB0139) / Galecto
Trial completion, Trial primary completion date: RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients (clinicaltrials.gov) - Jan 5, 2017
P1/2, N=60, Completed, Sponsor: Galecto Biotech AB
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2016
- ||| lenumlostat (GB2064) / Galecto
Trial completion: Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of PAT-1251 in Healthy Adult Subjects (clinicaltrials.gov) - Nov 30, 2016
P1, N=78, Completed, Sponsor: PharmAkea, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Completed
- ||| olitigaltin (GB0139) / Galecto
Enrollment closed: RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients (clinicaltrials.gov) - Sep 23, 2016
P1/2, N=60, Active, not recruiting, Sponsor: Galecto Biotech AB
Recruiting --> Completed Recruiting --> Active, not recruiting
- lenumlostat (GB2064) / Galecto
New P1 trial: Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of PAT-1251 in Healthy Adult Subjects (clinicaltrials.gov) - Aug 2, 2016
P1, N=78, Recruiting, Sponsor: PharmAkea, Inc.
- || olitigaltin (GB0139) / Galecto
Trial primary completion date: RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients (clinicaltrials.gov) - Jun 29, 2016
P1/2, N=60, Recruiting, Sponsor: Galecto Biotech AB
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2016 --> Sep 2016
- || olitigaltin (GB0139) / Galecto
Trial primary completion date: RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients (clinicaltrials.gov) - Feb 10, 2016
P1/2, N=60, Recruiting, Sponsor: Galecto Biotech AB
Trial primary completion date: Apr 2016 --> Sep 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- | olitigaltin (GB0139) / Galecto
New P1/2 trial: RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients (clinicaltrials.gov) - Oct 10, 2014
P1/2, N=60, Recruiting, Sponsor: Galecto Biotech AB